Marleen van den Horst

T: +31 70 376 06 21
View Marleen van den Horst on LinkedIn

Marleen van den Horst is partner in the IP and Technology practice group and heads the industry group Healthcare and Life Sciences. Marleen has more than 25 years of experience in conducting complex, cross-border proceedings on intellectual property. Specialised in patent law, she handles cases involving mechanical engineering, electrical engineering, chemistry and life sciences. From ship shutters, electronic Braille cells, floating solar panels, telecoms UMTS and LTE standard essential patents , machines for the manufacture of PVC-O pipes to medical equipment and pharmaceuticals. Marleen has achieved international recognition in the field of Life Sciences. In recent years, she has litigated and advised on patent and administrative litigation concerning, among other things, drugs whose active ingredients are ciclosporin, (es)omeprazole alendronate, escitalopram, modafinil, tramadol/paracetamol, glatiramer acetate, trastuzumab, zoledronate, rivastigmine, lenalidomide, ezetimibe+simvastatin, dasatinib, pemetrexed and sitagliptin as well as on CRISPR-Cas9 technology. Aside from litigation, Marleen also assists clients in negotiating and drawing up licences, technology transfers and distribution and cooperation agreements.

Selected directory listings

‘Working with Marleen van den Horst is a pleasant experience’.Legal 500, 2022

With enthusiasm and skill, Marleen van den Horst clearly shows why she rightly belongs at the top in the Netherlands’.Legal 500, 2022

Marleen van den Horst is very pragmatic and strong on regulatory issues’.Legal 500, 2022

Clients appreciates that she is “straight to the point in addressing client needs” and expands that she “doesn’t get lost in non-relevant things“. Chambers Europe, 2022

Van den Horst has a similar penchant for advanced technologies and complicated cases, particularly in the life sciences. “In addition to the expertise she brings, I am also very impressed by the quality of Marleen’s efforts and her motivation to continuously support us in realising our dream,” reports one client. “We fought our case in multiple jurisdictions and Marleen’s defence was tried, tested and true.”IAM Patent 1000, 2021

Marleen van den Horst is recognized as Leading Individual in the area of Healthcare & Life sciences, It’s great to work with lawyers who not only have top legal insight and knowledge, but also a genuinely commercial approach’. – Legal 500, 2021

“Marleen van den Horst is highly skilled and highly experienced. She is deeply engaged in the cases handled by her team, stimulating excellence. Her team has a strong “can-do” approach.’ ‘Marleen van den Horst is incredibly well connected and respected, a skillful strategist and great person to work with’.” – Legal 500, 2021

“Marleen Van den Horst routinely assists a clientele drawn from the pharmaceutical industry with patent infringement and invalidity cases. Clients rate the direction she brings to projects, one suggesting that “she is well organised and able to strategise cases well.”– Chambers Global & Europe, 2021

Professional activities

  • Marleen is a board member of the NeoKidney Foundation for the realisation of a wearable artificial kidney. She provides pro bono advice on patent and other legal issues.
  • Marleen is a member of several professional organisations and trade associations, such as EPLAW, AIPPI, LES, VF&R and VIEPA.
  • She is frequently asked as a speaker at international conferences, such as ERA’s annual EU Pharmaceutical law Conference, Fordham University’s annual IP Conference, World IP Forum, LESI and EPLAW.

Recently from this specialist

BarentsKrans has advised Axion BioSystems on its acquisition of CytoSMART

Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the Netherlands-based CytoSMART Technologies—an innovator in kinetic live-cell imaging analysis. The collaboration positions Axion for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. “Since Axion BioSystems’ inception, our focus has
Read more ›

Telecoms update | Court orders submission of third party license and settlement agreements in FRAND case and imposes confidentiality regime; AASI granted ex parte

Recently, two interesting judgments were published in separate SEP/FRAND proceedings. The first decision pertains to a confidentiality regime and the second to an ex parte AASI. Confidentiality regime In the SEP/FRAND proceedings between Philips et al. vs. Xiaomi et al the District Court of The Hague (“DC”) decided on 14 July 2021 (decision published in
Read more ›

Pharma update | Court of Appeal overturns ruling District Court in Astrazeneca v Menzis

In an earlier Pharma Update, we reported on the judgment of the District Court of The Hague of 14 October 2020 in which AstraZeneca AB (“AstraZeneca”) was ordered to pay damages to health insurer Menzis Zorgverzekeraar NV (“Menzis”) for having enforced a patent that was later invalidated against a generic company.   This judgment has now
Read more ›
More from this specialist